Delta-Fly Pharma,Inc. [4598.T]
TOKYO, Apr 01 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) reported the exercise status of its 11th warrant issue with an adjusted exercise price clause for the month of March 2026.
The warrants were issued to Macquarie Bank Limited on February 02, 2026. In March, 2,000 warrants were exercised, representing 0.0243% of the total issuance of 8,225,000 warrants. As of the end of February, there were 6,225,000 unexercised warrants outstanding. By the end of March, this number decreased to 6,019,000 warrants remaining unexercised.
Exercise activities during March included: - On March 2, 200 warrants were exercised. - From March 5 to March 6, a total of 412 shares were delivered against 412 warrants exercised. - On March 27, another 186 shares were transferred against 186 warrants exercised. At the end of February, the total issued share count was 1,000,000, including 198 treasury shares.
All exercise limits based on the Tokyo Stock Exchange's Listing Regulations Article 434 and the Securities Association’s Rules on Third Party Allocation Issues were adhered to, maintaining an exercise ratio of 2.43%.
🟡 Confidence: Standard AI-translated content.